Kalaris Therapeutics, Inc. 8-K

What Happened Kalaris Therapeutics (KLRS) filed an 8-K reporting that director Morana Jovan-Embiricos, Ph.D., resigned from the Board and the Audit Committee effective July 3, 2026. On the same date the Board, following the Nominating and Corporate Governance Committee’s recommendation, elected Laurie Keating to join the Board and the Audit Committee effective August 1, 2026; Keating will serve as a Class I director with a term expiring at the 2027 annual meeting.

Key Details

• Resignation: Dr. Morana Jovan-Embiricos resigned effective July 3, 2026; resignation not due to any disagreement with the Company.
• New director timing and term: Laurie Keating’s service begins August 1, 2026; term expires at the 2027 annual meeting.
• Compensation and equity: On Aug 1, 2026 (Grant Date) Keating will receive an option to purchase 18,000 shares at fair market value, vesting monthly over three years (full acceleration upon change in control). She will also receive $40,000 annual Board cash compensation, $7,500 additional annual cash for Audit Committee service, annual equity grants per policy, and reimbursement for meeting-related expenses.
• Governance and legal: Keating will join the Audit Committee, has no family ties or related-party transactions with the Company, and will enter the standard indemnification agreement requiring the Company potentially to indemnify her for certain expenses (e.g., attorneys’ fees, judgments, fines).

Why It Matters This 8-K documents a board change and a direct replacement on the Audit Committee, which affects corporate governance and oversight at Kalaris. Investors should note the timing (resignation July 3, 2026; new director effective Aug 1, 2026), the director compensation and equity grant (18,000‑share option), and that the Company reported no disagreements with the departing director and no related-party issues with the new director. These are routine governance updates but relevant for shareholders tracking board composition, committee membership, and potential dilution from equity awards.